

JEPT # 207464

Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: Potential boron delivery agents for neutron capture therapy.

Elena Sjuvarsson, Vijaya L. Damaraju, Delores Mowles, Michael B. Sawyer, Rohit Tiwari, Hitesh K. Agarwal, Ahmed Khalil, Sherifa Hasabelnaby, Ayman Goudah, Robin J. Nakkula, Rolf F. Barth, Carol E. Cass, Staffan Eriksson, Werner Tjarks

Department of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden (E.S., S.E.); Department of Oncology, University of Alberta, Edmonton, Alberta, Canada (V.L.D., D.M., M.B.S., C.E.C); Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, Ohio, USA (R.T., H.K.A., A.K., S.H., A.G., W.T.); Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt (A.K.); Division of Pharmaceutical Organic Chemistry, College of Pharmacy, Helwan University, Ain Helwan, Cairo, Egypt (S.H.); Division of Pharmacology, College of Veterinary Medicine, Cairo University, Giza, Egypt (A.G.); Department of Pathology, The Ohio State University, Columbus, Ohio, USA (R.J.N., R.F.B.).

JEPT # 207464

Running title: Cellular influx, efflux, and anabolism of 3CTAs

Corresponding author: Werner Tjarks, Division of Medicinal Chemistry and Pharmacognosy,
The Ohio State University, 500 W. 12 Ave, Columbus, OH 43210, USA. Phone: + 614 292-
7624, e-mail: tjarks.1@osu.edu

Number of text pages: 35

Number tables: 2

Number figures: 6

Number references: 32

Number of words in abstract: 213

Number of words in introduction: 554

Number of words in discussion: 998

List of abbreviations: 3CTAs, 3-carboranyl thymidine analogs; ATCC, American type culture collection; AZT, zidovudine; AZT-TP, AZT triphosphate; BSA, Bovine serum albumin; CMM, complete minimal medium; CMM/GLU, CMM/2% glucose; CNT, concentrative nucleoside transporter; DMEM, Dulbecco's modification of EMEM; dThd, thymidine; DTT, dithiothreitol; EMEM, Eagle's minimal essential medium; PeSt, penicillin streptomycin mixture; ENT, equilibrative nucleoside transporter; HPLC, high-performance liquid chromatography; NCT, neutron capture therapy; dNT-1, deoxynucleotidase-1; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; N5, 3-[5-(*o*-carboran-1-yl)pentan-1-yl]thymidine; N5-DP, N5-diphosphate; N5-MP, N5-monophosphate; N5-TP, N5-triphosphate; N5-2OH, 3-[5-{2-(2,3-dihydroxyprop-1-yl)-*o*-carboran-1-yl}pentan-1-yl]thymidine; N5-2OH-DP, N5-2OH diphosphate; N5-2OH-MP, N5-

JEPT # 207464

2OH monophosphate; NBMPR, nitrobenzylmercaptapurine ribonucleoside; NDPK, nucleoside diphosphate kinase; NK, nucleoside kinase; OAT, organic anion transporter; OCT, organic cation transporter; PBS, phosphate buffered saline; PEI, polyethylenimine; P-gp, P-glycoprotein; TLC, thin layer chromatography; TK1, thymidine kinase 1; TK2, thymidine kinase 2; TMPK, thymidine monophosphate kinase; TPase, thymidine phosphorylase; UMP-CMPK, uridine monophosphate-cytidine monophosphate kinase; Urd, uridine.

Recommended section: “Metabolism, Transport, and Pharmacogenomics”

Abstract

3-[5-{2-(2,3-Dihydroxyprop-1-yl)-*o*-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH) is a first generation 3-carboranyl thymidine analog (3CTA) that has been intensively studied as a boron-10 (^{10}B)-delivery agent for neutron capture therapy. N5-2OH is an excellent substrate of thymidine kinase 1 and its favorable biodistribution profile in rodents led to successful preclinical NCT of rats bearing intracerebral RG2 glioma. The present study explored cellular influx and efflux mechanisms of N5-2OH, as well as its intracellular anabolism beyond the monophosphate level. N5-2OH entered cultured human CCRF-CEM cells via passive diffusion whereas the multidrug resistance-associated protein 4 appeared to be a major mediator of N5-2OH monophosphate efflux. N5-2OH was effectively monophosphorylated in cultured murine L929 (TK1⁺) cells whereas formation of N5-2OH monophosphate was markedly lower in L929 (TK1⁻) cell variants. Further metabolism to the di- and triphosphate forms was not observed in any of the cell lines. Regardless of monophosphorylation, parental N5-2OH was the major intracellular component in both TK1⁺ and TK1⁻ cells. Phosphate transfer experiments with enzyme preparations showed that N5-2OH monophosphate, as well as the monophosphate of a second 3CTA (3-[5-(*o*-carboran-1-yl)pentan-1-yl]thymidine, N5), were not substrates of thymidine monophosphate kinase. Surprisingly, N5-diphosphate was phosphorylated by nucleoside diphosphate kinase although N5-triphosphate apparently was not a substrate of DNA polymerase. Our results provide valuable information on the cellular metabolism and pharmacokinetic profile of 3CTAs.

Introduction

A class of nucleoside bioconjugates designated as 3-carboranyl thymidine analogs (3CTAs) has been intensively studied in recent years as potential boron-delivery agents for Neutron Capture Therapy (NCT). Presumably, these agents accumulate selectively in malignant cells by thymidine kinase 1 (TK1)-mediated trapping through 5'-monophosphorylation (Khalil et al., 2013). TK1 is a deoxynucleoside kinase that is primarily active during the S-phase of the cell cycle (Arnér and Eriksson, 1995). The first generation 3CTA 3-[5-{2-(2,3-dihydroxyprop-1-yl)-*o*-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH, Fig.1) is an excellent substrate of TK1 and exhibits high uptake and retention in TK1 expressing tumor cells *in vivo* (Al-Madhoun et al., 2004; Barth et al., 2004, Barth et al., 2008). The favorable *in vivo* profile of N5-2OH led to successful preclinical NCT of rats bearing intracerebral RG2 glioma (Barth et al., 2008). However, almost nothing is known about cellular influx and efflux mechanisms of N5-2OH or its intracellular anabolism beyond the monophosphate level. The purpose of the present study was to gain information on these aspects of cellular 3CTA metabolism and pharmacokinetics because they are important in assessing the basic clinical potential of these agents.

Many purine and pyrimidine nucleosides enter cells by mediated transport processes (Plunkett and Saunders, 1991). Understanding transport mechanisms for nucleosides is important for evaluating clinical results because they have been implicated in resistance to nucleoside analog prodrugs, such as gemcitabine and capecitabine (Damaraju et al., 2003). There are four members of the equilibrative nucleoside transporter family (hENT1/2/3/4) and three of the concentrative nucleoside transporter family (hCNT1/2/3) (Cass et al., 1998). In addition, organic anion transporter (OAT) proteins mediate the exchange and transport of organic anions and show broad substrate selectivity including some cyclic nucleotides and antiviral nucleosides (Koepsell and Endou, 2004). Upon entering cells nucleosides are

converted to triphosphates by a succession of cellular kinases before incorporation into nucleic acids by DNA polymerase. Monophosphorylation is carried out by nucleoside kinases (NKs), diphosphorylation by nucleoside monophosphate kinases (NMPKs), and triphosphorylation by nucleoside diphosphate kinase (NDPK) (Arnér and Eriksson, 1995; Parks et al., 1973; Kreimeyer et al., 2001; Eriksson et al., 2002; Pasti et al., 2003). These phosphorylation steps are also critical in the activation of all biomedically relevant nucleoside analog prodrugs (Galmarini et al., 2001; Deville-Bonne et al., 2010). Three members of the family of human multidrug resistance-associated proteins (MRP4/5/8) are able to transport nucleoside monophosphate analogs out of cells against concentration gradients. The presence of MRP4/5 is associated with resistance to several nucleoside analogs used in anticancer and antiviral therapies, including zidovudine (AZT), adefovir, ganciclovir, abacavir, and gemcitabine (Pastor-Anglada et al., 2005; Borst et al., 2004; Ritter et al., 2005)..

In the present study, we have investigated intracellular uptake and retention of N5-2OH and its metabolites in cultured human CCRF-CEM (TK1⁺) and murine L929 (TK1⁺) cells and their TK1 deficient variants. The impact of various cellular influx and/or efflux transporters (*e.g.*, hENT1/2/3, hCNT1/2, organic cation transporters (OCTs), OATs, MRP4/5, P-gp) on cellular pharmacokinetics of N5-2OH and its metabolites was also explored. To study possible further metabolism of N5-2OH-MP, experiments with thymidine monophosphate kinase (TMPK), uridine monophosphate-cytidine monophosphate kinase (UMP-CMPK) and nucleoside diphosphate kinase (NDPK) were performed. The capacity of Klenow DNA polymerase I to incorporate the triphosphate form of 3-[5-(*o*-carboran-1-yl)pentan-1-yl]thymidine (N5, Fig.1), a 3CTA that is structurally related to N5-2OH (Khalil et al., 2013), into oligonucleotide templates during processive DNA synthesis was also explored.

Materials and Methods

Materials. The synthesis of N5/N5-2OH and their phosphates (Fig. 1) are described in *Supplemental Data*. Nitrobenzylmercaptapurine ribonucleoside (NBMPR), dilazep, unlabeled nucleosides, and other chemicals were obtained from Sigma Chemical Company (Mississauga, ON). Yeast nitrogen base was from Difco, Detroit, MI. [³H]Uridine ([³H]Urd) (35.5 Ci/mmol) and [³H]N5-2OH (59.1 and 117.5 Ci/mmol) were from Moravek Biochemicals (Brea, CA). [³²P]-ATP was from PerkinElmer, Boston, MA. Tissue culture (96-well) plates, cell culture media, horse serum, and fetal bovine serum (FBS) were from Gibco BRL (Burlington, ON). Ecolite was from ICN Pharmaceuticals (Montreal, PQ). The Cell Titer 96 Aqueous One Solution Cell Proliferation Assay Kit was from Promega (Madison, WI). Trypsin-EDTA and penicillin/streptomycin mixture (PeSt) were purchased from SVA (Uppsala, Sweden). Human recombinant TK1 and TMPK were prepared as described previously (Lunato et al., 1999 and Carnrot et al., 2008, respectively); human recombinant cytosolic UMP-CMPK and human erythrocyte NDPK were purchased from OriGene Technologies, Inc. (Rockville, MD) and Sigma-Aldrich Life Science (St. Louis, MO), respectively. Light paraffin oil and silicone 550 oil were purchased from Sigma-Aldrich, Life Science.

Cell cultures and preparation of cell extracts. Murine fibroblast cell lines, TK1 positive ATCC-CCL-34 (L929 TK1⁺) and TK1 negative ATCC-CCL-1.3 (L929 TK1⁻), and the human T-lymphoblast CCRF-CEM (ATCC-CCL-119) cell line (CEM TK1⁺) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). A subline of CCRF-CEM, deficient in thymidine kinase activity (CEM TK1⁻), was originally provided by B. Ullman (Oregon State University, Corvallis, OR). Cell cultures were maintained according to ATCC recommendations and grown at 37°C in a humidified incubator in the presence of 5% CO₂. L929 TK⁺ cells were grown in Eagle's Minimal Essential Medium (EMEM)

JEPT # 207464

supplemented with 10% horse serum, 2 mM L-glutamine and 1% PeSt. L929 TK⁻ cells were grown in Dulbecco's modification of EMEM (DMEM) media supplemented with 10% FBS, 4 mM L-glutamine, 1% PeSt; CCRF-CEM TK1⁺ and TK1⁻ cells were grown as suspension cultures in RPMI 1640 with 10% FBS, 10 mM HEPES, 1 mM sodium pyruvate and 1% PeSt. For uptake experiments CCRF-CEM and L929 cells were seeded at cell densities of 5×10^5 cells/ml in growth media for 24 h to ensure actively proliferating cells with population densities not exceeding 2×10^6 cells/ml.

Metabolic studies. *Methods described in the following correspond to data shown in Figs. S1/S2 (Supplemental Data) and Table 2.* Prior to metabolic assays, L929 cells were washed once in ice cold phosphate buffered saline (PBS) and re-suspended in growth medium containing 10 μ M [³H]-labeled nucleoside solution (1 part [³H]-labeled nucleoside and 9 parts cold nucleoside) of N5-2OH or thymidine (dThd). Following 2 hr incubation at 37°C in a humidified incubator in the presence of 5% CO₂, medium was removed from L929 cells, cells were washed with ice-cold PBS twice, trypsinized with 0.5% trypsin-EDTA for 5 min, and collected by centrifugation at 600 \times g for 5 min at 4°C. After centrifugation, cell pellets were re-suspended with 1 ml PBS, cell numbers were determined, and cells were re-centrifuged. Cells pellets were re-suspended in 200 μ l 70% MeOH/ 30% 20 mM EDTA on ice, frozen in liquid nitrogen and immediately sonicated (3 \times 1 min) on ice. Supernatants were removed after centrifugation at 16000 \times g for 10 min at 4°C, frozen in dry ice and MeOH/EDTA was evaporated by lyophilization. Samples were dissolved in the HPLC mobile phase and 200 μ l aliquots were used for reverse-phase high-performance liquid chromatography (HPLC) on a (HPLC) C18 column (250 \times 4.6 mm; 5 μ m particles) to analyze intracellular levels of [³H]N5-2OH and [³H]N5-2OH-MP. The mobile phase was A=0.1% TFA in water, B=0.1% TFA in acetonitrile at a flow rate of 1 ml/min. The gradient

JEPT # 207464

program used was as follows: 0–27 min 35-70% B; 27–28 min, 70-35% B; 28–40 min, 35% B.

Intracellular [^3H]dThd, [^3H]dThd-MP, and [^3H]dThd-DP levels in cell extracts were analyzed by DEAE Sepharose chromatography. Cells were trypsinized with 0.5% trypsin-EDTA and centrifuged at $600 \times g$ for 5 min. Cell pellets were resuspended in pre-chilled lysis buffer containing of 10 mM Tris base, 50 mM NaCl, 1 mM MgCl_2 , 15 mM NaF, 10 mM dithiothreitol (DTT), 0.5% NP-40, 10 mM EDTA and incubated on ice for 30 min. The cell extract was centrifuged twice at $16000 \times g$ for 10 min at 4°C . The supernatant was diluted with 0.5 M NH_4HCO_3 to a final concentration of 0.5 mM and applied to DEAE Sepharose. [^3H]dThd-MP eluted at a concentration of 50-75 mM NH_4HCO_3 and [^3H]dThd-DP eluted at a concentration of 100-150 mM NH_4HCO_3 . Combined elutes containing either [^3H]dThd-MP or [^3H]dThd-DP were concentrated by freeze drying and re-dissolved in water.

Values represent pmoles of [^3H]N5-2OH and [^3H]dThd metabolites per 10^6 cells and are from a representative experiment, which was repeated three times with similar results.

Nucleoside transport in *Saccharomyces cerevisiae*. *Methods described in the following correspond to data shown in Fig. 2A and Table 1.* Yeast were separately transformed with plasmids (pYPhENT1, pYPhENT2, pYPhCNT1, pYPhCNT2, or pYPhCNT3) encoding hNTs (hENT1, hENT2, hCNT1, hCNT2, or hCNT3, respectively), as described elsewhere (Vickers et al., 2002; Zhang et al., 2003). Thus, yeast genetically manipulated in this way expresses each of the five human nucleoside transporters. Uptake of $1 \mu\text{M}$ [^3H]Urd into yeast was measured, as previously described (Vickers et al., 2002; Zhang et al., 2005; Zhang et al., 2003), using the semi-automated cell harvester (Micro96 HARVESTER; Skatron Instruments, Lier, Norway). Yeast strains were maintained in complete minimal medium (CMM) containing 0.67% yeast nitrogen base amino acids (as required to maintain

JEPT # 207464

auxotrophic selection), and 2% glucose (CMM/GLU). Yeast cells were grown in CMM/GLU to an absorbance at 600 nm (A_{600}) = 0.5-1.0, washed twice, and re-suspended to A_{600} = 4.0. Yeast were incubated at ambient temperature with graded concentrations (0-1 mM) of N5-2OH in the presence of 1 μ M [3 H]Urd in transport buffer (pH 7.4) containing 20 mM Tris, 3 mM K_2HPO_4 , 1 mM $MgCl_2$, 1.4 mM $CaCl_2$, and 5 mM glucose with 144 mM NaCl. Yeast were also incubated with 1 μ M [3 H]Urd in the absence of test compound as positive controls. Values from cultures without test compound were used to calculate the “% Control”. Urd self-inhibition was used as an internal control to define maximum inhibition of mediated transport. Transport reactions were initiated by rapid mixing of 50 μ l yeast suspensions with or without graded concentrations of N5-2OH with 50 μ l of $2 \times$ [3 H]nucleoside in 96-well microtiter plates. Yeast cells were collected on filter mats using a Micro96 Cell Harvester and rapidly washed with deionized water. Individual filter circles, corresponding to wells of the microtiter plates, were removed from filter mats with forceps and transferred to vials for quantification of radioactivity by scintillation counting.

Data were subjected to nonlinear regression analysis using GraphPad Prism software (version 4.03; GraphPad Software Inc., San Diego, CA) to obtain the concentration of test compound that inhibited growth of treated cells by 50% relative to that of untreated cells (IC_{50} values). IC_{50} values were determined from concentration-effect curves. Each experiment was conducted with nine concentrations and six replicates per concentration and was repeated three times to obtain accurate IC_{50} values.

Nucleoside transport assays in CEM cells. *Methods described in the following correspond to data shown in Figs. 2B/C and 3C/D.* CCRF-CEM wild-type cells are known to only express hENT1 (Belt et al., 1993). Inhibition of 1 μ M [3 H]Urd uptake (30 s) was measured at ambient temperature in CEM cells in transport buffer (pH 7.4) containing 20 mM Tris, 3 mM K_2HPO_4 , 1 mM $MgCl_2$, 1.4 mM $CaCl_2$, and 5 mM glucose with 144 mM

JEPT # 207464

NaCl in absence or presence of graded concentrations (0-0.5 mM) of N5-2OH. At the end of the uptake intervals, permeant-containing solutions were removed by aspiration, cells were spun down and quickly rinsed twice with transport buffer, and solubilized with 5% Triton X-100. Radioactivity in solubilized extracts was measured by liquid scintillation counting. Uptake values were expressed as pmoles/ 10^6 cells and converted to % control activity and graphs were generated using GraphPad Prism. Each experiment was conducted three times with triplicate measurements for each condition.

Inhibition of [^3H]N5-2OH and [^3H]Urd uptake was determined by exposing CEM cells to 1 μM [^3H]N5-2OH or 1 μM [^3H]Urd in absence or presence of either 100 μM dilazep (ENT inhibitor), 500 μM probenecid (OAT inhibitor), 500 μM cimetidine (OCT inhibitor), 100 μM N5-2OH or 1 mM Urd for 1 min after which uptake was terminated by spinning cells through oil. Cells were washed by centrifugation and cell-associated radioactivity was determined by scintillation counting. Each experiment was conducted with six replicates per condition and was repeated three times with similar results.

Methods described in the following correspond to data shown in Figs. 3A and 4.

Nucleoside uptake was measured at ambient temperature in actively proliferating cells (2×10^6 cells/ml) using the oil-stop transport method (Harley et al., 1982). CEM TK1⁺ and CEM TK1⁻ cells were grown as described above. Cells were harvested by centrifugation (600 $\times g$, 5 min), washed twice with PBS and then resuspended in 100 μl transport buffer (5×10^6 cells). The time courses for initial rates of [^3H]N5-2OH uptake in CEM TK1⁺ cells were determined using a rapid sampling procedure (10 sec) that was initiated by addition of 100 μl cells to 100 μl of [^3H]N5-2OH solution to a final concentration of 1 μM and terminated by addition of 100 μl of 1 mM N5-2OH solution followed by centrifugation (16,000 $\times g$, 30 s) through transport oil (Fig. 3A). Cellular uptake of [^3H]N5-2OH and [^3H]dThd in CEM TK1⁺ and CEM TK1⁻ cells were determined at 30, 60, 90, and 120 min using the procedure described

JEPT # 207464

above. Final nucleoside concentrations were 1 μM and termination was accomplished by addition of 1 mM N5-2OH or dThd solutions followed by centrifugation through transport oil (Fig.4). Cell pellets were solubilized in 5% Triton X-100 and cell-associated radioactivity was determined by liquid scintillation counting.

The role of hENT1 mediated uptake of N5-2OH into CEM TK1⁺ was studied in the presence of a range of concentrations of the hENT1 specific inhibitor NBMPR (0.1 μM & 1.0 μM). Cells were preincubated with inhibitors for 30 min, washed twice with PBS and incubated with 1 μM [³H]N5-2OH for 1 h (Fig. 3A).

Uptake values were expressed as pmoles/ 10^6 cells (Fig. 3A) or % Control (Fig.4), which is the mean cpm of cell-associated radioactivity compared to total cpm used for initiation of nucleoside transport (100%). Graphs were generated using GraphPad Prism. All experiments were performed in triplicates.

Cytotoxicity assays. *Methods described in the following correspond to data shown in Fig. 3B.* The Cell Titer 96 proliferation assay kit was used to quantify drug induced cytotoxicity. Unless otherwise noted, CEM cells seeded in 96-well plates were exposed to graded concentrations (0-100 μM) of N5-2OH in the absence or presence of 1 μM NBMPR for 72 h after which they were treated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent for determination of cytotoxicity. IC₅₀ values were calculated from nonlinear regression analyses of values plotted as percentages of control values against the logarithm of drug concentrations.

Efflux studies. *Methods described in the following correspond to data shown in Fig. 6.* CCRF-CEM wild-type are known to express efflux pump proteins approximately in the following order: MRP4 >> MRP5 > P-gp (Peng et al., 2008). For efflux studies CEM-TK1⁺ cells (1×10^6 per ml) were seeded in T75 flasks in growth media consisting of RPMI-1640 (without phenol red) with 10% FBS, 10 mM Hepes, 1 mM sodium pyruvate and 1% PeSt and

JEPT # 207464

grown overnight. Cells were incubated for 1 h with 1 μM [^3H]N5-2OH, washed twice in ice-cold PBS, and then incubated in growth medium without [^3H]N5-2OH for 150 min. To determine the amount of [^3H]N5-2OH-MP in cells at the beginning of efflux, a portion of the cell-containing mixture was taken immediately, cells were pelleted by centrifugation for 1 min at 12,000 $\times g$, resulting cell pellets were solubilized by 5% Triton X-100, and radioactivity was determined by scintillation counting. The total cpm in 1 ml-portions of cell-free medium was determined by scintillation counting at different time points. Levels of [^3H]N5-2OH and [^3H]N5-2OH-MP in the growth media of CEM-TK1⁺ cells were analyzed by HPLC at the indicated timed points.

For efflux inhibition experiments, CEM-TK1⁺ cells were incubated with 1 μM of nucleoside mixture, comprised of 0.1 μM radiolabeled [^3H]N5-2OH and 0.9 μM unlabeled N5-2OH, for 2 h at 37°C in growth media as described above with either dipyridamole, indomethacin or verapamil at a concentration of 100 μM . Cells were washed twice with ice-cold PBS, followed by addition of prewarmed media, and incubated for 2 h at 37°C. [^3H]N5-2OH-MP concentrations in the media from cells were determined by HPLC. Values shown are % cpm of [^3H]N5-2OH-MP in media with inhibitors relative to 100% of control values without inhibitors.

Phosphate transfer assay. *Methods described in the following correspond to data shown in Figs. S4 (Supplemental Data) and 5A/B.* The adenosine 5'-triphosphate transfer assay was performed with 0.05 μM [$\gamma^{32}\text{P}$]-ATP (10 $\mu\text{Ci}/\mu\text{l}$), 100 μM ATP, 50 mM Tris-HCl (pH 7.6), 5 mM MgCl_2 , 100 mM KCl, 0.5 mg/ml bovine serum albumin (BSA), 10 mM DTT and different concentrations of nucleoside analog. Reactions were initiated by adding either TK1, UMP-CMPK, TMPK or NDPK followed by incubation at 37°C and termination by short boiling after different time points. Four μl of reaction solutions were applied to polyethylenimine (PEI)-cellulose thin layer chromatography (TLC) plates. Depending on the

JEPT # 207464

enzyme reaction, chromatography was performed with different buffers. For identification of nucleoside diphosphates, chromatography was performed with 0.2 M NaH₂PO₄ buffer. Triphosphate products of dTTP and N5-TP from the NDPK assay were separated with 0.4 M NaH₂PO₄ and 30% isopropanol. Phosphates were detected by autoradiography following 1 h exposures of TLC plates to a phosphor imaging plate (BAS cassette 2040, Fujifilm, Tokyo, Japan) using the phosphor-imaging system, Fuji BAS 2500/LAS 1000 (Fujifilm), in combination with an Image Reader V 1.7E.

Coupled synthesis of dTTP and AZT-TP. *Methods described in the following correspond to data shown in Figs. S5 (Supplemental Data) and 5C/D.* A coupled synthesis of dTTP and AZT-TP was performed using 200 μM of dThd or AZT with 0.05 μM [γ ³²P]-ATP (10 μCi/μl) and 100 μM ATP in phosphate transfer assay buffer (50 mM Tris-HCl (pH 7.6), 5 mM MgCl₂, 100 mM KCl, 0.5 mg/ml BSA, 10 mM DTT). The reaction was initiated by adding a mixture of recombinant human TK1 (100 ng), TMPK (100 ng), UMP-CMPK (100 ng) and NDPK (100 ng) followed by incubation at 37°C and termination by boiling after different time points. For separation of nucleoside monophosphates and diphosphates in the coupled reactions, chromatography was performed for 8-12 h using isobutyric acid: NH₄OH:H₂O (66:1:33) (v/v) as the mobile phase. Products of the kinase reactions were detected by autoradiography as described above.

DNA polymerase running start assays. *Methods described in the following correspond to data shown in Figs. 5C/D.* To prepare primer templates for running start reactions, the 16-mer primer 5'-CGC CCA CGC GGC AGA G-3' (Invitrogen, Carlsbad, CA) was 5'-end labeled with T4 polynucleotide kinase (as described in the manufacturer's procedure) and [γ ³²P]ATP, desalted on a PD SpinTrap™ G-25 column (GE Healthcare, Pataskala, OH) in TEN buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, 100 mM NaCl), and annealed in a 1:2 ratio to the respective 36-mer templates 3'-GCG GGT GCG CCT GCT CTT ACC TCT TCT CTC

JEPT # 207464

TTC TCT-5' (Invitrogen, Carlsbad, CA) in TEN buffer by heating to 75°C for 5 min followed by slow cooling to room temperature. Incorporation of triphosphates into the primer template was carried out in a volume of 20 μ l for 45 min at 37°C with the 5U Klenow fragment of *E. coli* DNA polymerase I (New England BioLabs Inc., Ipswich, MA), 0.25 pmol of labeled primer-template, and different concentrations of deoxynucleoside triphosphates.

Incorporation of triphosphates from coupled reactions into primer templates was carried out in final volumes of 20 μ l by adding 5 μ l of the original reaction product or 5 μ l of diluted reaction product. Four dilution ratios (1/2, 1/4, 1/8, 1/16) were generated by adding appropriate quantities of reaction buffer to the original reaction product.

Results

Effects of N5-2OH on [³H]Urd uptake in yeast and CEM cells. The inhibitory activity of N5-2OH on transporter-mediated uptake of 1 μ M [³H]Urd was determined using hENT1/2 and hCNT1/2/3-producing yeast, as described in *Materials and Methods*. Effects of N5-2OH on transporter mediated Urd uptake were assessed in concentration-dependent inhibition of [³H]Urd transport experiments to determine IC₅₀ values for each of the five recombinant transporters. Representative concentration-effect curves for inhibition of hENT1-mediated Urd transport by N5-2OH are shown in Fig. 2A. It was evident that N5-2OH produced dose-dependent inhibition of [³H]Urd transport at μ M concentrations. IC₅₀ values obtained from similar experiments with yeast producing each of the five transporters are summarized in Table 1. Results indicate that only hENT1 interacted significantly with N5-2OH.

Since N5-2OH inhibited hENT1 mediated [³H]Urd transport in yeast radiotracer experiments, its inhibition of hENT1-mediated transport of [³H]Urd was also evaluated in human CEM cells, which possess hENT1 as the major nucleoside transporter (Belt et al., 1993). Fig. 2B shows effects of graded N5-2OH concentrations on 1 μ M [³H]Urd transport in

JEPT # 207464

CEM cells. These concentration-effect studies yielded IC_{50} values of $36 \pm 5 \mu\text{M}$ for N5-2OH (Fig. 2B) for inhibition of hENT1-mediated Urd transport. Fig. 2C shows effects of fixed concentrations of N5-2OH on Urd transport rates. Data was analyzed using LineWeaverBurk plot, which shows competitive inhibition of Urd transport by N5-2OH. Further analysis by Dixon plot gave a K_i value of $22 \pm 1.6 \mu\text{M}$.

Effects of inhibitors on uptake of $1 \mu\text{M}$ [^3H]N5-2OH or $1 \mu\text{M}$ [^3H]Urd and of NBMPR on cytotoxicity of N5-2OH in CEM cells. Initial rates of uptake of $0.1 \mu\text{M}$ [^3H]N5-2OH measured for up to 10 seconds with CEM cells are shown in Fig. 3A. Uptake appeared to be linear and the presence of either $0.1 \mu\text{M}$ or $1 \mu\text{M}$ NBMPR had no effect on initial rates, *i.e.*, 1.33 ± 0.26 moles/sec/ 10^6 cells (without NBMPR) compared to 1.21 ± 0.28 moles/sec/ 10^6 cells with NBMPR (Fig. 3A). Results of cytotoxicity studies with NBMPR were consistent with the lack of effect on initial rates of uptake in that exposures to graded concentrations (0 - $100 \mu\text{M}$) of N5-2OH in the absence or presence of NBMPR ($1 \mu\text{M}$) for 72 h yielded similar results (Fig. 3B).

Uptake of $1 \mu\text{M}$ [^3H]N5-2OH or $1 \mu\text{M}$ [^3H]Urd into CEM cells was measured in the absence or presence of either $100 \mu\text{M}$ dilazep (ENT inhibitor), $500 \mu\text{M}$ probenecid (OAT inhibitor), $500 \mu\text{M}$ cimetidine (OCT inhibitor), $100 \mu\text{M}$ N5-2OH, or 1mM Urd. Results obtained with N5-2OH (Fig. 3C) demonstrated minimal inhibition of uptake by dilazep, probenecid, cimetidine or excess Urd. In contrast, Urd uptake (Fig. 3D) in CEM cells was inhibited by both dilazep and excess Urd as expected in the case of mediated uptake. Excess N5-2OH inhibited [^3H]uridine uptake, indicating interaction with hENT1, whereas excess N5-2OH had a very small to negligible effect on uptake of [^3H]N5-2OH uptake.

Uptake and anabolism of N5-2OH in cultured TK^+ and TK^- cells. Earlier studies with N5 and N5-2OH have shown a 5 to 10 fold difference in uptake and retention of these 3CTAs in cultured L929 TK^+ and TK^- cells (Barth et al, 2004). Using the same cell lines as well as

CEM TK1⁺ and TK1⁻ cells, but different experimental conditions and compound detection methods, we characterized intracellular [³H]N5-2OH metabolites. In accordance with results obtained with the TMPK enzyme assay (see below), only [³H]N5-2OH and its monophosphate were detected within cell extracts (*Supplemental Data*, Figs. S1 and S2). The uptake mechanism of N5-2OH by CEM TK1⁺ and TK1⁻ cells, both at long and short periods of incubation, was investigated. The time course of cellular uptake and metabolism of [³H]N5-2OH was followed for up to 120 min, as described in the *Materials and Methods* section. Uptake and retention of dThd and N5-2OH (and their metabolites) reached steady state levels after 60 min of incubation in both CEM TK1⁺ and CEM TK1⁻ cells (Fig.4). Levels of [³H]dThd in TK1⁻ cells were more than 10 fold lower than that in TK1⁺ cells (Fig. 4A), whereas the difference in [³H]N5-2OH levels between cell lines was less pronounced (Fig. 4B). The intracellular level of [³H]dThd found in TK1⁻ cells after 60 min was 10%, whereas that in TK1⁺ cells was 45%. In contrast, intracellular levels of [³H]N5-2OH were approximately 40% and 55%, respectively.

In a chase experiment, a two-hour labeling period with [³H]N5-2OH was followed by 24 h incubation in compound free medium resulting in a retention of 7.8% of total cpm in L929 TK1⁺ cells and 6.8% of total cpm in L929 TK1⁻ cells (data not shown). The intracellular concentrations of [³H]N5-2OH and [³H]N5-2OH-MP in TK1⁺ cells were 4.6 ± 0.5 and 1.5 ± 0.12 pmol/10⁶ cells, respectively (Table 2). Retention of [³H]N5-2OH-MP in TK1⁻ cells was approximately 5-fold lower than in TK1⁺ cells whereas the level of [³H]N5-2OH was similar in both cell lines (Table 2).

A control experiment was performed with [³H]dThd, *i.e.*, a 2 h labeling period followed by 24 h incubation in compound free medium and, in this case, 9.6% of total cpm was retained in L929 TK1⁺ cells and 0.3% of total cpm in L929 TK1⁻ cells (data not shown). Intracellular concentrations of dThd, dTMP and dTDP in L929 TK1⁺ were 1.5 ± 0.16 , $5.8 \pm$

JEPT # 207464

0.56 and 0.5 ± 0.03 pmol/ 10^6 cells, respectively, and 1.4 ± 0.09 , 0.039 ± 0.004 , and 0 pmol/ 10^6 cells, respectively, in L929 TK1⁻ cells (Table 2).

The obtained data showed that N5-2OH could be taken up and retained in a TK1 independent fashion in two pairs of TK1 positive and negative cell lines. In the case of L929 TK1⁺ cells, [³H]N5-2OH-MP was retained significantly longer than in L929 TK1⁻ cells, indicating that formation of N5-2OH-MP was catalyzed by TK1. There was no indication for further phosphorylation of this metabolite in L929 cells (*Supplemental Data*, Figs. S1 and S2).

Phosphorylation studies with N5 and N5-2OH monophosphates using recombinant kinases. It is well established that N5, N5-2OH, and numerous other 3CTAs are good substrates of TK1 (Khalil et al., 2013). To study the further anabolism of N5 and N5-2OH, a series of experiments with human nucleoside mono- and diphosphate kinases were performed using appropriate phosphorylated substrates. Two recombinant human pyrimidine nucleoside monophosphate kinases, UMP-CMPK and TMPK, were tested for their capacity to phosphorylate N5- and N5-2OH-MP. Monophosphates (MP) and diphosphates (DP) of N5 and N5-2OH (Fig. 1) were synthesized as described in *Supplemental Data* (Schemes S1 and S2). N5-MP and N5-DP were used in these studies as surrogate systems for the corresponding phosphates of N5-2OH because of anticipated stability issues during synthesis of the latter ones, in particular N5-2OH-DP (*Supplemental Data*). This approach was warranted since N5 and N5-2OH appeared to have generally similar enzymatic properties (Al-Madhoun et al., 2004; Hasabelnaby et al., 2012).

Both recombinant UMP-CMPK and TMPK showed high activities with their endogenous substrates dCMP and dTMP, whereas N5-MP or N5-2OH-MP substrates did not produce detectable amounts of diphosphate products (Fig. 5A), even at extended reaction times (*Supplemental Data*, Fig. S4). Computational docking studies reinforced our experimental

finding that N5-2OH-MP is not a substrate for TMPK (*Supplemental Data*, Fig. S3). Docking of dTMP into the crystal structure of TMPK reproduced the pose of co-crystallized dTMP accurately (lowest RMSD = 1.03 Å) whereas N5-2OH-MP docked in marked distance to the original dTMP binding site (lowest RMSD = 6.43 Å).

It was demonstrated by TLC that human NDPK phosphorylated N5-DP to N5-TP with a phosphorylation efficiency of approximately 30% relative to that of dTDP (Fig. 5B). Increasing the reaction time from 30 to 60 min led to an increase of N5-TP formation by a factor of 2, whereas the rate of dTTP formation using dTDP as the substrate remained unchanged, indicating a substantially lower efficiency of N5-DP to serve as substrate for NDPK.

DNA incorporation studies. The capacity of the Klenow DNA polymerases I enzyme to incorporate N5-TP, AZT-TP and dTTP into oligonucleotide templates during processive DNA synthesis, i.e. using running start primer-templates, was investigated (Copeland et al., 1992; Eriksson et al., 1995). For these studies we used a coupled synthesis of dTTP and AZT-TP by adding a mixture of recombinant human TK1, TMPK, UMP-CMPK, and NDPK to either dThd or AZT. For the synthesis of N5-TP we used N5-DP as a substrate for NDPK as described above. As a control for each enzyme step we carried out a series of assays using only TK1 or combinations of TK1 with TMPK or UMP-CMPK. A TLC analysis of mono and diphosphate products in the enzyme reactions with dThd and AZT is shown in Fig. S5 (*Supplemental Data*). The running start primer reaction was performed as described in *Materials and Methods* and a gel analysis of the reaction products with Klenow DNA polymerase I and dTTP, AZT-TP and N5-TP using a running start primer-template DNA is shown Figs. 5C and 5D. Incubation of the 16-mer primer template with T4 polynucleotide kinase and [γ ³²P]ATP led to [32 Pi]-labeled 18-mer nucleotide product. Both dTTP and coupled synthesis dTTP product were incorporated by Klenow DNA polymerase I into the

running start primer with the formation of [³²Pi]-labeled 19-mer nucleotide products. The coupled synthesis AZT-TP product was also a substrate for Klenow DNA polymerase I, whereas N5-TP apparently was not, since no incorporation of N5-TP into the oligonucleotide was detected (Fig. 5D).

Cellular efflux of [³H]N5-2OH. Efflux of N5-2OH was measured in CEM-TK1⁺ cells, which were incubated with 1 μM [³H]N5-2OH for 1 h and then maintained in nucleoside-free growth medium for 150 min, as described in *Materials and Methods*. One ml of medium was removed at different time points for the determination of total radioactivity from [³H]N5-2OH and its metabolites (Fig. 6A) and HPLC analysis of [³H]N5-2OH and [³H]N5-2OH-MP released from cells (Fig. 6B).

Removing [³H]N5-2OH from the media led to a rapid loss of labeled nucleoside from the cells. There was decrease in radioactivity of about 30% 60 min after the transfer of cells to nucleoside-free media. Following this, radioactivity levels reached a plateau (Fig. 6A). Time-dependent efflux of [³H]N5-2OH and [³H]N5-2OH-MP is shown in Fig. 6B. About 86% of the total radioactivity in the media at 150 min was [³H]N5-2OH, with the remaining 14% being [³H]N5-2OH-MP. During the incubation period from 60 to 150 min, the ratio of extracellular to intracellular [³H]N5-2OH-MP was 15% to 85% (data not shown).

We also studied effects of specific efflux inhibitors – *e.g.*, dipyridamole, indomethacin and verapamil on extracellular N5-2OH-MP levels (Fig. 6C). Results showed that dipyridamole, an inhibitor of MRP4 and MRP5 (Ritter et al., 2005), and indomethacin, a relatively selective inhibitor of MRP4 (Ritter et al., 2005), decreased the efflux of N5-2OH-MP by approximately 80%. Verapamil, an inhibitor of P-gp (Summers et al., 2004), decreased efflux of N5-2OH MP from CEM TK⁺ cells only by approximately 30%.

Discussion

Data from earlier studies suggested that phosphorylation by TK1 was required for uptake and retention of the N5-2OH in malignant cells both *in vitro* and *in vivo* (Al-Madhoun et al., 2004; Barth et al., 2004; Barth et al., 2008). However, little information is available regarding the complete intracellular metabolism of N5-2OH including its potential incorporation into DNA. In addition, mechanisms of cellular membrane traversal of N5-2OH and its metabolites are largely unexplored.

Only hENT1 mediated Urd transport was inhibited by N5-2OH, both in yeast and CEM cells. In experiments with CEM cells, Urd uptake inhibition by N5-2OH was shown to be competitive. However, the high affinity hENT1 transport inhibitor NBMPR had minimal effects on uptake of N5-2OH, suggesting that hENT1 played no major role in the uptake of N5-2OH by CEM cells. Furthermore, the cytotoxicity of N5-2OH for CEM cells in the presence of 1 μ M NBMPR was the same as in its absence, thus confirming that hENT1 was not important in mediating uptake of N5-2OH into CEM cells.

Uptake of 1 μ M [3 H]N5-2OH into CEM cells was further evaluated in presence or absence of several transport inhibitors, including dilazep, NBMPR, probenecid, and cimetidine as well as excess non-radioactive Urd and N5-2OH. Excess non-radioactive N5-2OH inhibited [3 H]N5-2OH uptake to a low extent, suggesting the possible presence of an unidentified uptake mechanism. All other transport inhibitors had little or no effect on uptake of [3 H]N5-2OH into cells. In contrast, [3 H]Urd uptake in CEM cells was inhibited by both dilazep and excess Urd, which is consistent with mediated uptake by hENT1, a transporter known to be selectively expressed in CEM cells (Belt et al., 1993). The effect of excess non-radioactive N5-2OH on uptake of 1 μ M [3 H]Urd by recombinant hENT1 in yeast suggested that N5-2OH was binding to the permeant binding site of hENT1 and competitively blocked [3 H]Urd uptake. Overall, these results strongly suggest that cellular uptake of N5-2OH by

CEM cells occurred mainly through passive diffusion, a conclusion supported by the minimal effect of NBMPR on the moderate cytotoxicity observed for N5-2OH.

In our metabolic studies with CEM TK1⁺/TK1⁻ and L929 TK⁺/TK1⁻ cells, important similarities and differences between [³H]dThd and [³H]N5-2OH became apparent. These studies confirmed that the presence of TK1 was crucial for accumulation of dThd nucleotides (dTMP and dTDP) in cells. In the absence of TK1 activity, uptake and retention of [³H]dThd was drastically reduced and only minor quantities of dTMP were observed. In the case of [³H]N5-2OH, however, substantial uptake and retention of the parental nucleoside was also observed in TK1⁻ cells. Significant formation of N5-2OH-MP by TK1 takes place in TK1⁺ cells. However, even in these cells the parental nucleoside was the major intracellular component reaching concentration levels comparable to that of TK⁻ cells. There was no indication for further phosphorylation of N5-2OH-MP in TK1⁺ L929 cells (*Supplemental Data*). Thus, we cannot exclude the possibility that hitherto unidentified mechanisms specific to TK1⁺ wild-type cells and their TK1⁻ variants used in our studies contributed to the observed cellular uptake pattern of N5-2OH. It is also conceivable that this 3CTA binds non-specifically to lipophilic cellular components, as the agent itself is very lipophilic (Al-Madhoun et al. 2004).

To substantiate the metabolic profile found for N5-2OH in cell culture experiments, a series of experiments with recombinant human pyrimidine nucleoside monophosphate kinases, UMP-CMPK and TMPK, were performed to test their capacity to phosphorylate N5-MP and N5-2OH-MP. Both monophosphate kinases showed high activity with their endogenous substrates dCMP and dTMP, respectively. In contrast, when N5-MP and N5-2OH-MP were used as substrates, no diphosphate products were observed. This finding correlated with the metabolite analysis of N5-2OH in our cell culture studies. Surprisingly, however, human NDPK did catalyze the phosphorylation of N5-DP to N5-TP although with a

substantially lower efficiency compared to endogenous dTDP.

Both efficacy as boron delivery agents for NCT and cytotoxicity of 3CTAs may be related to their potential incorporation into DNA, as has been discussed by us previously (Barth et al. 2004; Tjarks et al., 2007). Thus, we studied the capacity of Klenow DNA polymerase I to incorporate N5-TP, AZT-TP, and dTTP into oligonucleotide templates during processive DNA synthesis, *i.e.*, using a running start primer-template system. Both AZ-TP and dTTP, generated via coupled enzymatic synthesis, were good substrates for Klenow DNA polymerase I. In contrast, N5-TP, synthesized enzymatically from NDPK/N5-DP, apparently was not incorporated into template oligonucleotide by this polymerase. This result is consistent with data from a previous study, indicating that 3-methyl-dTTP could not be incorporated into DNA (Huff and Topal, 1987). The apparent lack of DNA incorporation of N5-TP supports the moderate *in vitro* and *in vivo* toxicity observed for 3CTAs (see also Fig. 3B) (Al-Madhoun et al. 2004; Barth et al. 2004; Barth et al. 2008). On the other hand, the absence of DNA incorporation did not appear to hamper the efficacy of N5-2OH in preclinical NCT studies, as previously reported (Barth et al., 2008).

Our studies indicated that N5-2OH-MP was subject to cellular efflux from CCRF-CEM wild-type cells and that both dipyridamole and indomethacin inhibited the efflux of N5-2OH-MP, whereas verapamil had minimal effects on N5-2OH-MP efflux. Previous studies have shown that MRP4 is a major efflux pump in CCRF-CEM wild-type cells (Peng et al., 2008). Thus, the strong inhibition of N5-2OH-MP efflux by the selective MRP4 inhibitor indomethacin suggests a key role for this pump as a regulator of the intracellular accumulation of N5-2OH-MP.

In conclusion, N5-2OH traverses cell membranes via passive diffusion and its monophosphate appears to be a substrate of MRP4 in CCRF-CEM wild-type cells. In addition, 3CTAs, such as N5 and N5-2OH, appear to possess a unique metabolic profile

JEPT # 207464

among established biomedical/clinical nucleoside analogs because they are metabolized exclusively by TK1 within the range of enzymes that can bind the dThd scaffold intracellularly. Previous studies have shown that N5-2OH is not a substrate of thymidine kinase 2 (TK2) and catabolizing thymidine phosphorylase (TPase) and deoxynucleotidase-1 (dNT-1) did not catalyze dephosphorylation of N5-2OH-MP (Al-Madhoun et al. 2004; Tjarks et al., 2007).

Acknowledgements

The authors thank Dr. Michael V. Darby for supervising work in the radiochemistry laboratory at The Ohio State University.

Authorship Contributions

Participated in research design: Tjarks, Eriksson, Cass, Damaraju, Sjuvarsson, Barth, Nakkula

Conducted experiments: Sjuvarsson, Mowles, Agarwal, Khalil, Tiwari, Nakkula

Contributed new reagents or analytic tools: Hasabelnaby, Tiwari, Khalil, Agarwal, Goudah

Performed data analysis: Sjuvarsson, Damaraju, Agarwal, Khalil, Tiwari

Wrote or contributed to the manuscript: Sjuvarsson, Eriksson, Damaraju, Cass, Sawyer, Tjarks, Tiwari, Khalil, Barth

References

- Arnér ES and Eriksson S (1995) Mammalian deoxyribonucleoside kinases. *Pharmacol Ther* **67**:155-186.
- Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, and Eriksson S (2004) Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. *Cancer Res* **64**:6280-6286.
- Barth RF, Yang W, Al-Madhoun AS, Johnsamuel J, Byun Y, Chandra S, Smith D, Tjarks W, and Eriksson S (2004) Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumours. *Cancer Res* **64**:6287-6295.
- Barth RF, Yang W, Wu G, Swindall M, Byun Y, Narayanasamy S, Tjarks W, Tordoff K, Moeschberger ML, and Eriksson S et al. (2008) Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. *Proc Natl Acad Sci* **105**:17493-17497.
- Belt JA, Marina NM, Phelps DA, and Crawford CR (1993) Nucleoside transport in normal and neoplastic cells. *Adv Enzyme Regul* **33**:235-252.
- Borst P, Balzarini J, Onoa N, Reid G, de Vries H, Wielinga P, Wijnholds J, and Zelcer N (2004) The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. *Antiviral Res* **62**:1-7.
- Carnrot C, Wang L, Topalis D, and Eriksson S (2008) Mechanisms of substrate selectivity for *Bacillus anthracis* thymidylate kinase. *Protein Sci* **17**:1486-1493.
- Cass EC, Young JD, and Baldwin SA (1998) Recent advances in the molecular biology of nucleoside transporters of mammalian cells. *Biochem Cell Biol* **76**:761-770.
- Copeland WC, Chenz MS, and Wangs TS-F (1992) Human DNA polymerases α and β are able to incorporate anti-HIV deoxynucleotides into DNA. *J Biol Chem* **267**:21459-21464.
- Deville-Bonne D, El Amri C, Meyer P, Chen Y, Agrofoglio LA, and Janine J (2010) Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural

JEPT # 207464

and catalytic properties. *Antiviral Res* **86**: 101-120.

Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, and Cass CE

(2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. *Oncogene* **22**:7524-7536.

Eriksson S, Xu B, and Clayton DA (1995) Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA Polymerase. *J Biol Chem* **270**:18929-18934.

Eriksson S, Munch-Petersen B, Johansson K, and Eklund H (2002) Structure and function of cellular deoxyribonucleoside kinases. *Cell Mol Life Sci* **59**:1327-1346.

Galmarini CM, Mackey JR, and Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. *Leukemia*, **15**:875-890.

Harley ER, Paterson AR, and Cass CE (1982) Initial rate kinetics of the transport of adenosine and 4-amino-7-(beta-D-ribofuranosyl)pyrrolo[2,3d]pyrimidine (tubercidin) in cultured cells. *Cancer Res* **42**:1289-1295.

Hasabelnaby S, Goudah A, Agarwal HK, Abd Alla MS, and Tjarks W (2012) Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors. *Eur J Med Chem* **55**:325-334.

Huff AC and Topal MD (1987) DNA damage at thymine N-3 abolishes base-pairing capacity during DNA synthesis. *J Biol Chem* **262**:12843-12850.

Khalil A, Ishita K, Ali T, and Tjarks W (2013) N3-substituted thymidine bioconjugates for cancer therapy and imaging. *Future Med Chem* **5**:677-692.

Koepsell H, and Endou H (2004) The SLC22 drug transporter family. *Pflugers Arch* **447**:666-676.

JEPT # 207464

- Kreimeyer A, Schneider B, Sarfati R, Faraj A, Sommadossi JP, Veron M, and Deville-Bonne D (2001) NDP kinase reactivity towards 3TC nucleotides. *Antiviral Res* **50**:147–156.
- Lunato AJ, Wang J, Woollard JE, Anisuzzaman AKM, Ji W, Rong F-G, Ikeda S, Soloway AH, Eriksson S, Ives DH, et al. (1999) Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl) thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. *J Med Chem* **42**:3378-3389.
- Parks RE Jr., and Agarwal RP (1973) Nucleoside diphosphokinases, in *The Enzymes*, 3rd Edition, Vol 8 (Boyer PD ed.) pp 307–333, Academic Press, New York.
- Pasti C, Gallois-Montbrun S, Munier-Lehmann H, Veron M, Gilles AM, and Deville-Bonne D (2003) Reaction of human UMP-CMP kinase with natural and analog substrates. *Eur J Biochem* **270**:1784–1790.
- Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoiz I, Martínez-Picado J, and Casado FJ (2005) Cell entry and export of nucleoside analogues. *Virus Res* **107**:151-164.
- Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari A, Fu L, Cass CE, Chen ZS (2008) Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. *Leuk Res* **32**: 799-809.
- Plunkett W, and Saunders PP (1991) Metabolism and action of purine nucleoside analogs. *Pharmacol Ther* **49**:239-268.
- Ritter CA, Jedlitschky G, Meyer zu Schwabedissen H, Grube M, Koöck K, and Kroemer HK (2005) Cellular export of drugs and signalling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). *Drug Metab Rev* **1**:253–278.

JEPT # 207464

- Summers MA, Moore JL, and McAuley JW (2004) Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. *Ann Pharmacother* **38**:1631-1634.
- Tjarks W, Tiwari R, Byun Y, Narayanasamy S, and Barth RF (2007) Carboranyl thymidine analogues for neutron capture therapy. *Chem Commun*:4978-4991.
- Vickers MF, Kumar R, Visser F, Zhang J, Charania J, Raborn RT, Baldwin SA, Young JD, and Cass CE. (2002) Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in *Saccharomyces cerevisiae*. *Biochem Cell Biol* **80**:639-644.
- Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, and Cass CE. (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in *Saccharomyces cerevisiae*. *Mol Pharmacol* **64**:1512-1520.
- Zhang J, Smith KM, Tackaberry T, Visser F, Robins MJ, Nielsen LP, Nowak I, Karpinski E, Baldwin SA, Young JD, and Cass CE (2005) Uridine binding and transportability determinants of human concentrative nucleoside transporters. *Mol Pharmacol* **68**:830-839.

JEPT # 207464

Footnotes

1. E.S. and V.L.D. made equal contributions to the manuscript.
2. The studies presented in this paper were supported by the National Cancer Institute [Grant 5R01 CA127935], funds from The Ohio State University College of Pharmacy, the Swedish Research Council, and the Canadian Cancer Society Research Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the mentioned organizations/institutions.

Figure Legends

Figure 1: Structures of N5 and N5-2OH and their phosphates.

Figure 2: Effects of N5-2OH on [³H]Urd uptake in yeast (A) and CEM cells (B). Yeast or CEM cells were incubated with 1 μM [³H]Urd for 10 min or 30 sec, respectively, in the absence or presence of increasing N5-2OH concentrations (0-1000 μM). Shown are experiments performed with six and three replicates per concentration respectively for yeast and CEM cells and data are expressed as mean ± S.D. Error bars are not shown where S.D values are smaller than the size of the symbol. (C) Effect of increasing concentrations of N5-2OH on the uptake of [³H]Urd in CEM cells is shown. The effects of 0 (■), 5 (▲), 25 (▼) or 50 (◆) μM N5-2OH on Urd uptake rates were assessed and values with mean ± S.D are shown in each panel. Each experiment was repeated three times.

Figure 3: Effects of transport inhibitors on uptake of [³H]N5-2OH and [³H]Urd in CEM cells and toxicity of N5-2OH in CEM cells in absence or presence of NBMPR. (A) CEM cells incubated with [³H]N5-2OH in the absence (○, solid line) or presence of 0.1 μM NBMPR (□, dashed line) or 1 μM NBMPR (●, dotted line). Transport was measured over 10 sec. (B) The effect of NBMPR on the toxicity of N5-2OH to CEM cells, which were exposed to graded concentrations (0-300 μM) of N5-2OH in the absence (○, solid line) or presence of 1 μM NBMPR (□, dashed line) for 72 h. Cell viability was measured by the MTS assay as described in *Materials and Methods*. Cytotoxicity was determined by expressing values as % control of untreated cells. The results (mean ± S.D) shown are average of three experiments each conducted with six replicates per point and repeated three times. (C &D) Uptake of 1 μM [³H]N5-2OH (C) or 1 μM [³H]Urd (D) into CEM cells. Uptake was measured for 1 min in the absence or presence of 100 μM dilazep (ENT inhibitor), 500 μM probenecid (OAT inhibitor), 500 μM cimetidine (OCT inhibitor), 100 μM N5-2OH or 1 mM Urd and cell-

associated radioactivity was quantitated. Values (pmoles/ 10^6 cells; mean \pm S.D) plotted are from a representative experiment, which was repeated three times with similar results.

Figure 4: Cellular uptake of [^3H]dThd (A) and [^3H]N5-2OH (B) into CEM-TK1⁺ (●) and CEM TK1⁻ (■) cells during incubation with nucleosides for up to 2 hrs. Time courses of cellular uptake of [^3H]N5-2OH and [^3H]dThd were determined by addition of 100 μl of cells to 100 μl of labeled nucleoside solution to a final concentration of 1 μM and further processing as described in *Materials and Methods*. % Control is the mean cpm of cell-associated radioactivity compared to total cpm used for initiation of nucleoside transport (100%).

Figure 5: (A) Autoradiograms of a TLC analysis of the products from a [$\gamma^{32}\text{P}$]ATP phosphate transfer assays with UMP-CMPK (1-4) or TMPK (6-9) using dCMP (1, 6), dTMP (2, 7), N5-MP (3, 8) and N5-2OH-MP (4, 9) as substrates. Lane 5 = [$\gamma^{32}\text{P}$]ATP only.

(B) Autoradiogram of a TLC analysis of the diphosphate products from a [$\gamma^{32}\text{P}$]ATP phosphate transfer assays with NDPK using dTDP (2,3) and N5-DP (4,5) as substrates. The assays were performed for 30 (2, 4) and 60 (3, 5) min. [$\gamma^{32}\text{P}$] ATP (1) served as a control.

(C&D) Autoradiograms of a gel analysis of the reaction products of dTTP, AZT-TP, and N5-TP with Klenow DNA polymerase I using a running start primer-template DNA. (C 1-6) Incorporation of dTTP into the running start primer at six different concentrations of dTTP (0, 1, 10, 25, 50 and 100 μM). (C 7-9) Incorporation of the dTTP product from a coupled synthesis using dThd and TK1, TMPK, and NDPK, as described in *Materials and Methods*. (Dilutions: C7 = 1/16, C8 = 1/8, C9 = 1/4). The 16-mer primer template was incubated with T4 polynucleotide kinase and $\gamma^{32}\text{P}$ -ATP for 10 min at 37°C leading to formation of a ^{32}P -labeled 18-mer nucleotide product (C1&D1). Additions of dTTP (C 1-6) or dTTP (D 2-5),

JEPT # 207464

AZT-TP (D 6-9) and N5-TP (D 10, 11) from coupled reactions and Klenow DNA polymerase to the labeled 18-mer only leads to the formation of ^{32}P -labeled 19-mer nucleotide products for dTTP and AZT-TP (Dilutions: D2/D6 = 0, D3/D7 = 1/2, D4/D8 = 1/4, D5/D9 = 1/8, D10 = 0, D = 1/2). Reactions were terminated by addition of 2 volumes of 90% formamide, 0.25 M EDTA. Products were analyzed on 15% polyacrylamide-7 M urea gels and detected by phosphoimaging (1h).

Figure 6: Time-dependent efflux of total [^3H]N5-2OH metabolites (A) and [^3H]N5-2OH monophosphate to the growth media (B) of CEM TK1⁺ cells. (C) Effects of transport inhibitors on the efflux of N5-2OH-MP from CEM TK1⁺ cells. CEM TK1⁺ cell were incubated 1 h with 1 μM [^3H]N5-2OH washed with PBS and then incubated in growth media without [^3H]N5-2OH for 150 min. The total intracellular cpm (A, ■) and total cpm in free media (A, ●) were determined by scintillation counting at different time points after removal of the labeled nucleoside. N5-2OH (B, ●) and N5-2OH-MP (B, ■) in free media were analyzed by HPLC as described in *Materials and Methods*. Results shown are the average of three experiments. For the efflux inhibition experiments, cells were incubated with 1 μM labeled nucleoside solution [^3H]N5-2OH for 2 h at 37°C in growth media in the presence of 100 μM dipyridamole, indomethacin or verapamil. [^3H]N5-2OH-MP in media from cells was determined by HPLC as described in *Materials and Methods*. Values show the % of cpm of [^3H]N5-2OH-MP in media with inhibitors to 100% of the control experiment without inhibitors in media.

Tables

TABLE 1. Effects of N5-2OH on [³H]Urd uptake in *S. cerevisiae* producing recombinant hENT1, hENT2, hCNT1, hCNT2, or hCNT3.

Shown are IC₅₀ values that represent N5-2OH concentrations at which uptake of 1 μM [³H]Urd was inhibited by 50% over a fixed time period as determined by computer-generated concentration-effect curves.

Transporters	IC ₅₀ ± S.E (μM)
hENT1	44 ± 5
hENT2	300 ± 47
hCNT1	580 ± 50
hCNT2	360 ± 90
hCNT3	700 ± 30

JEPT # 207464

TABLE 2. Retention of intracellular [³H]N5-2OH and [³H]dThd metabolites in L929-TK1⁺ and L929-TK1⁻ cells.


The intracellular [³H]N5-2OH and [³H]N5-2OH-MP levels in cell extracts from L929 TK1⁺ and L929 TK1⁻ were analyzed by HPLC. Intracellular [³H]dThd, [³H]dThd-MP and [³H]dThd-DP levels in cell extracts from TK1⁺ and TK1⁻ cells were analyzed by DEAE sepharose chromatography, as described in *Materials and Methods*. The values represent pmoles of [³H]N5-2OH and [³H]dThd metabolites per 10⁶ cells and are from a representative experiment, which was repeated three times with similar results. **N:** N5-2OH & dThd; **MP:** N5-2OH-MP & dTMP; **DP:** dTDP; **ND** - not detected.

Cells	L9292 TK1 ⁺			L929 TK1 ⁻		
	N	MP	DP	N	MP	DP
N5-2OH	4.6±0.5	1.5±0.12	ND	6.3±0.7	0.3±0.02	ND
dThd	1.5±0.16	5.8±0.56	0.5±0.03	1.4±0.09	0.039±0.004	ND

JEPT # 207464

Figures

Fig. 1



N5-2OH: $R_1 = \text{OH}$, $R_2 = \text{CH}_2\text{C}^*\text{H}(\text{OH})\text{CH}_2\text{OH}$

N5-2OH-MP: $R_1 = \text{OPO}_3^{2-}$, $R_2 = \text{CH}_2\text{C}^*\text{H}(\text{OH})\text{CH}_2\text{OH}$

N5: $R_1 = \text{OH}$, $R_2 = \text{H}$

N5-MP: $R_1 = \text{OPO}_3^{2-}$, $R_2 = \text{H}$

N5-DP: $R_1 = \text{OP}_2\text{O}_6^{3-}$, $R_2 = \text{H}$

N5-TP: $R_1 = \text{OP}_3\text{O}_9^{4-}$, $R_2 = \text{H}$

Fig. 2






Fig. 3




Fig. 4










Fig. 5



a = 19 mer; b = 18 mer

Fig. 6



SUPPLEMENTAL DATA

Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: Potential boron delivery agents for neutron capture therapy.

Elena Sjuvarsson, Vijaya L. Damaraju, Delores Mowles, Michael B. Sawyer, Rohit Tiwari, Hitesh K. Agarwal, Ahmed Khalil, Sherifa Hasabelnaby, Ayman Goudah, Robin J. Nakkula, Rolf F. Barth, Carol E. Cass, Staffan Eriksson, and Werner Tjarks

Department of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden (E.S., S.E.); Department of Oncology, University of Alberta, Edmonton, Alberta, Canada (V.L.D., D.M., M.B.S., C.E.C); Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, Ohio, USA (R.T., H.K.A., A.K., S.H., A.G., W.T.); Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt (A.K.); Division of Pharmaceutical Organic Chemistry, College of Pharmacy, Helwan University, Ain Helwan, Cairo, Egypt (S.H.); Division of Pharmacology, College of Veterinary Medicine, Cairo University, Giza, Egypt (A.G.); Department of Pathology, The Ohio State University, Columbus, Ohio, USA (R.J.N., R.F.B.).

E.S. and V.L.D. made equal contributions to the manuscript.

Corresponding Author: Werner Tjarks, Division of Medicinal Chemistry and Pharmacognosy, The Ohio State University, 500 W. 12 Ave, Columbus, OH 43210, USA. Phone: + 614 292-7624, e-mail: tjarks.1@osu.edu

Table of Contents

	Page
S.1. Chemistry	S3 – S10
S.2. HPLC analysis of intracellular N5-2OH metabolites	S11 – S12
S.3. Computational studies	S13
S.4. Autoradiographic studies	S14
S.5. Figures	S15 –S19
S.6. List of Abbreviations	S20
S.7. References	S21

S.1. Chemistry

S.1.1. General Experimental Part

^1H -, ^{13}C -, and ^{31}P NMR spectra were obtained on a Bruker DRX 400 at The Ohio State University College of Pharmacy (400 MHz for ^1H , 100 MHz for ^{13}C , and 161 MHz for ^{31}P). Chemical shifts (δ) are reported in ppm from internal deuterated chloroform or methanol. Coupling constants are reported in Hz. ^{13}C and ^{31}P nuclear magnetic resonance (NMR) spectra are fully decoupled. High resolution–electrospray ionization (HR-ESI) mass spectra (MS) were obtained on a Micromass LCT spectrometer at The Ohio State University Campus Chemical Instrumentation Center.

Silica gel 60 (0.063-0.200 mm), used for gravity column chromatography, and silica gel 60 (0.015-0.049 mm), used for flash column chromatography, were purchased from Dynamic Adsorbents Inc. (Norcross, GA). Reagent-grade solvents were used for column chromatography. Precoated glass-backed thin layer chromatography (TLC) plates with silica gel 60 F254 (0.25 mm layer thickness) from Dynamic Adsorbents Inc. were used for TLC. General compound visualization for TLC was achieved by UV light. Carborane-containing compounds were selectively visualized by spraying the plate with a 0.06% $\text{PdCl}_2/1\%$ HCl solution and heating at 120°C , which caused the slow (15-45 s) formation of a gray spot due to the reduction of Pd^{2+} to Pd^0 .

Anhydrous solvents were purchased directly either from Acros Organics (Morris Plains, NJ) or from Sigma Aldrich (Milwaukee, WI). Tetrahydrofuran (THF) was distilled from sodium and benzophenone indicator under argon. All reactions were carried out under argon.

Preparative high pressure liquid chromatography (HPLC) was performed with a Gemini $5\mu\text{m}$ C18 column (21.20 mm x 250 mm, $5\mu\text{m}$ particle size) supplied by Phenomenex Inc. (Torrance,

CA) on a Hitachi HPLC system (L-2130) with a Windows based data acquisition and Hitachi Diode array detector (L-2455). Analytical HPLC was carried out with a Gemini 5 μ C18 110A Column (250 x 4.6 mm) supplied by Phenomenex Inc. using the HPLC system mentioned above. Radiometer HPLC was performed with Beckman System Gold HPLC system with 166 UV/Vis detector and 127 solvent module.

S.1.2. Solvent systems for HPLC analysis

S.1.2.1 Preparative HPLC

Method A:

Time (min)	Triethylammonium hydrogen carbonate buffer (100 mM)	Acetonitrile (0.1 % TFA) Concentration	Flow rate (ml/min)
	A (%)	B (%)	
0	100	0	1
1	100	0	7
110	40	60	7
111	100	0	7
120	100	0	1

S.1.2.2. Analytical HPLC

Method B:

Time (min)	Water (0.1 % TFA) Concentration A (%)	Acetonitrile (0.1 % TFA) Concentration B (%)	Flow rate (ml/min)
0	55	45	1
25	55	45	1
34	0	100	1
35	55	45	1
45	55	45	1

Method C:


Time (min)	Water (0.1 % TFA) Concentration A (%)	Acetonitrile (0.1 % TFA) Concentration B (%)	Flow rate (ml/min)
0.00	65.0	35.0	1.0
27.0	30.0	70.0	1.0
28.0	65.0	35.0	1.0
40.0	65.0	35.0	1.0

S.1.3. Detailed synthetic procedures

S.1.3.1. Previously described compounds

N5-2OH (Hasabelnaby et al. 2012), N5-2OH monophosphate (Al-Madhoun et al., 2004), N5 (Lunato et al., 1999) as well as compounds 5 (Hasabelnaby et al. 2012) and 6 (Davisson et al., 1987) (see below) were synthesized as described previously. HPLC retention times for N5 (Method B), N5-2OH (Method C), and N5-2OH-MP (Method C) were 33.04, 16.45 and 13.87, respectively.

S.1.3.2. Synthesis of N5-MP



Scheme S1: Synthesis of N5-monophosphate

S.1.3.2.1. 5'-Bis(2,2,2-trichloroethyl) ester of N5 (2).


A mixture of N5 (compound 1, 340 mg, 0.75 mmol), bis(2,2,2-trichloroethyl) phosphorochloridate (330 mg, 0.87 mmol), anhydrous pyridine (50 μ L, 1.04 mmol) in 10 ml of

acetonitrile was stirred at 0°C for 5 days. The reaction was quenched by adding 5 ml of MeOH and stirred for additional 30 min at room temperature. Following solvent evaporation, the residue was extracted with 20 ml of diethylether and washed with 10 ml of 0.1 M HCl. The organic layer was dried over MgSO₄, filtered, and evaporated. The residue was purified by silica gel column chromatography using hexanes: ethyl acetate (9:1) to give compound **2** (0.27 g, 45%). ¹H NMR (MeOH-d₄) δ: 7.55 (s, 1H), 6.30 (t, *J* = 6.8, 1H), 4.8 (ds, 4H), 4.44-4.51 (m, 4H), 4.11 (m, 1H), 3.88 (t, *J* = 7.1, 2H), 2.24-2.32 (m, 4H), 2.93 (s, 3H), 1.50-1.61 (s, 4H), 1.30 (m, 2H). ¹³C NMR (MeOH-d₄) δ: 164.53, 151.45, 135.57, 110.41, 95.26, 86.90, 85.32, 77.77, 76.53, 71.00, 69.34, 62.88, 41.25, 39.82, 37.83, 29.24, 27.27, 26.45, 12.66. MS (HR-ESI) for C₂₁H₃₆B₁₀Cl₂N₂NaO₈P [(M+Na)⁺]. Calcd: m/z 819.1290 Found: m/z 819.1309. HPLC retention time (Method B): 21.71.

S.1.3.2.2. Disodium salt of the 5'-monophosphate of N5 (**3**).

To a solution of 20 mg (0.31 mmol) of zinc powder in 10 ml of acetic acid, compound **2** (30 mg, 0.04 mmol) was added and the resulting suspension was stirred for 10 h. The reaction mixture was filtered and evaporated. The residue was purified by HPLC (Method A) and the desired compound was passed through a column containing Amberlite 200 (sodium form) to furnish the disodium salt of the 5'-monophosphates of N5 (**3**, 8.5 mg, 39%). ¹H NMR (MeOH-d₄, 400 MHz) δ: 7.91 (s, 1H), 6.36 (t, *J* = 6.74, 1H), 4.52 (m, 2H), 4.04 (m, 3H), 3.9 (t, *J* = 6.94, 2H), 2.20-2.31 (m, 4H), 1.96 (s, 3H), 1.47-1.64 (m, 4H), 1.31 (m, 2H). ¹³C NMR (MeOH-d₄, 100 MHz) δ: 165.50, 152.38, 136.70, 111.14, 88.04, 87.14, 77.27, 73.17, 63.62, 61.96, 41.89, 38.56, 30.73, 29.95, 27.96, 27.15, 13.43. ³¹P NMR (MeOH-d₄, 161 MHz) δ: 4.31. MS (HR-ESI) for C₁₇H₃₄B₁₀N₂O₈PNa [(M+Na)⁺]. Calcd: m/z 556.2954 Found: m/z 556.2939.

S.1.3.3. Synthesis of N5-DP



Scheme S2: Synthesis of N5-Diphosphate

S.1.3.3.1. 5-(*o*-Carboran-1-yl)pentyl tosylate (**5**).

To a solution of compound **4** (0.3 g, 0.6 mmol) in THF (30 ml) was added a 1 M solution of TBAF (0.9 ml, 0.9 mmol) in THF at -78°C . The reaction mixture was stirred at room temperature for 1 h. Distilled water (10 ml) was added and excess THF was removed under reduced pressure. The residue was extracted with ethyl acetate, the combined organic layers were washed with brine, dried over anhydrous MgSO_4 , and filtered. The residue was purified by silica gel column chromatography using hexanes: ethyl acetate (8:2) to give compound **5** (158 mg, 69%). ^1H NMR (CDCl_3) δ : 7.77 (d, $J = 8.26$, 2H), 7.35 (d, $J = 8.26$, 2H), 4.00 (t, $J = 6.1$, 2H), 3.45 (s, 1H), 2.46 (s, 3H), 2.15 (t, $J = 8.1$, 2H), 1.64 (m, 2H), 1.41 (m, 2H), 1.31 (m, 2H). ^{13}C NMR (CDCl_3) δ : 145.07, 133.07, 130.05, 127.99, 75.04, 69.96, 61.24, 37.84, 28.60, 28.43, 24.96, 21.80.

S.1.3.3.2. 3-(*o*-Carboranylpentyl)-5'-tosyl-thymidine (7).

A mixture of compound **5** (130 mg, 0.34 mmol), compound **6** (122 mg, 0.31 mmol), and K_2CO_3 (85 mg, 0.62 mmol) in 10 ml of DMF/acetone (50/50) was stirred for 2 days at 50°C. The solvent was evaporated and the residue was purified by silica gel column chromatography using DCM: acetone (85: 15) to give compound **7** (50 mg, 27%). 1H NMR ($CDCl_3$) δ : 7.79 (d, $J = 8.6$, 2H), 7.38 (m, 3H), 6.37 (t, $J = 7.2$, 1H), 4.53 (m, 1H), 4.26 (d, $J = 2.51$, 1H), 4.09 (m, 1H), 3.88 (m, 2H), 3.59 (br s, 1H), 2.47 (s, 3H), 2.33-2.39 (m, 2H), 2.16-2.24 (m, 4H), 1.94 (s, 3H), 1.59 (m, 2H), 1.49 (m, 2H), 1.32 (m, 2H). ^{13}C NMR ($CDCl_3$) δ : 163.44, 151.00, 145.82, 133.42, 132.34, 130.34, 127.98, 110.95, 85.43, 83.70, 75.39, 71.42, 68.85, 61.13, 41.04, 40.50, 37.92, 28.82, 27.07, 26.26, 21.86, 13.33. MS (HR-ESI) for $C_{24}H_{39}B_{10}N_2O_7SNa [(M+Na)^+]$. Calcd: m/z 631.3452 Found: m/z 631.3487.

S.1.3.3.3. Trisodium salt of the 5'-diphosphate of N5 (8).

To a solution of compound **7** (10 mg, 0.016 mmol) in anhydrous CH_3CN (16 μL , 1M), tris(tetra-*n*-butylammonium) hydrogen pyrophosphate (22 mg, 0.24 mmol) was added. The mixture was stirred for 2 days and methanol (0.5 ml) was added. Following filtration, the resulting solution was purified by HPLC (Method A) to give the 5'-diphosphate of N5. The obtained material was dissolved in methanol and passed through an ion exchange column [Amberlite 200 (sodium form)] to give the trisodium salt of the 5'-diphosphate of N5 (compound **8**, 8 mg, 73%). 1H NMR ($MeOH-d_4$) δ : 7.83 (s, 1H), 6.33 (t, $J=6.71$, 1H), 4.60 (m, 1H), 4.23 (m, 1H), 4.17 (m, 1H), 4.02 (br s, 1H), 3.90 (t, $J= 7.23$, 2H), 3.19 (m, 1H), 2.83 (m, 2H), 2.27 (m, 2H), 1.97 (s, 3H), 1.52-1.65 (m, 2H), 1.49 (m, 2H), 1.28 (m, 2H). ^{13}C NMR ($MeOH-d_4$) δ : 165.58, 152.43, 136.46, 111.15, 87.57, 86.91, 72.03, 66.38, 66.34, 60.05, 42.48, 40.76, 32.15,

28.67, 28.29, 24.83, 13.42. ^{31}P NMR (MeOH-d₄, 161 MHz) δ : -6.30, -8.36. MS (HR-ESI) for $\text{C}_{17}\text{H}_{36}\text{B}_{10}\text{N}_2\text{O}_{11}\text{P}_2$ $[\text{M}]^+$. Calcd: m/z 616.2846 Found: m/z 616.2840. HPLC retention time (Method B): 16.67.

Additional Comments: The mono- and diphosphate of N5 (3 & 8) were used in studies with recombinant kinases (see main manuscript) as surrogate systems for the corresponding phosphates of N5-2OH. The synthesis of the diphosphate of N5-2OH would have required a relatively complex synthetic procedure involving an acetonide-protected form of N5-2OH (Hasabelnaby et al., 2012). We noticed that the diphosphate of N5 was unstable under slightly acidic conditions resulting in the cleavage of the phosphate moieties. The necessary acidic removal of an acetonide group from the diphosphate of an acetonide-protected form of N5-2OH most likely would have resulted in simultaneous cleavage of phosphate moieties. Synthesis of the diphosphate of N5 does not require acidic conditions and N5 and N5-2OH appear to have generally similar enzymatic properties (Hasabelnaby et al., 2012; Lunato et al., 1999) Thus, the use of N5-phosphates as surrogates for the corresponding N5-2OH phosphates is warranted.

S.2. HPLC analysis of intracellular N5-2OH metabolites

S.2.1. General comments

Procedures for cell culture experiments and protocols for the enzymatic production of N5-2OH-MP are described in the *Materials and Methods* section of the main article.

S.2.2. Figure legends

Figure S1: Reverse-phase (C18) HPLC analysis of intracellular N5-2OH metabolites in L929 TK1⁺ and L929 TK1⁻ cells.

A. N5-2OH [red] and its monophosphate product [blue] in a control assay using TK1 protein with 100 μ M N5-2OH (100 μ M N5-2OH and 0.1 μ M [³H]N5-2OH) as described in *Materials and Methods*. **B.** Intracellular metabolites of N5-2OH in L929-TK1⁺ cells [red] and L929 TK1⁻ cells [blue] incubated for 60 min with 1 μ M [³H]N5-2OH. The [³H]-radiolabeled products were identified by HPLC using a reversed-phase-18 Discovery® C18 column (250 x4.6 mm; 5 μ m particles). The mobile phase was A = 0.1% TFA in Water, B = 0.1% TFA in acetonitrile at a flow rate of 1 ml/min. The gradient used was as follows: 0–27 min, 35-70% B; 27–28 min, 70-35% B; 28–40 min, 35% B.

Additional comments: As shown in the chromatograms there was a significant amount of N52OH-MP found in extracts from TK1⁺ cells (red). Both L929 TK1⁺ and L929 TK1⁻ cells contained substantial and similar levels of non-phosphorylated [³H]N5-2OH. On the other hand, there were no detectable levels of di and/or tri-phosphates in cell extracts from L929 TK1⁺ or TK1⁻ cells. In a separate HPLC analysis (data not shown) it was established that synthetically and enzymatically produced N5-DP and N5-TP eluted in fractions 7 and 2, respectively, using the same solvent system. In chromatogram B, the signal for [³H]N5-2OH in L929 TK1⁻ cells [blue] is distributed both into fraction 18 and 19.

Figure S2. Partisil SAX HPLC analysis of intracellular N5-2OH metabolites in L929 TK1⁺ and of enzymatically produced N5-2OH-MP.

A: Radio-HPLC of ³H-materials in L929 TK1⁺ cells following 2 h-incubation with 0.1 μM [³H]N5-2OH / 0.9 μM N5-2OH. **B:** Enzymatically produced [³H]N5-2OH-MP. **C:** Enzymatically produced non-radioactive N5-2OH-MP. The ³[H]-radiolabeled products were identified by HPLC on a Partisil SAX Column (250 x 4.6 mm, Whatman/GE Healthcare, Piscataway, NJ) using Beckmann analytical HPLC system with radioflow detector (500TR, Packard, San Diego, CA). The mobile phase was A = 20% acetonitrile in water, B = phosphate buffer pH 7.2 (sodium phosphate dibasic, 0.5 M) at a flow rate of 1 ml/min. The gradient used was as follows: 0–5 min, 100-0% B; 5–20 min, 0-100% B; 20–40 min, 100-0% B.

Additional comments: In addition to signals for [³H]N5-2OH, radio-HPLC did not show significant signals for metabolites other than [³H]N5-2OH-MP in cell extracts from L929 TK1⁺ cells that were exposed to [³H]N5-2OH (Figure S2). One additional signal for an unidentified tritiated cellular component was detected (Figure S2 A), which eluted with the solvent front. It did not seem to be nucleos(t)ide material. It could have been [³H]H₂O produced during cell culturing. HPLC-retention times for N5-2OH-MP produced both enzymatically (Figure S2 B & C) and during cell culture (Figure S2 A) were 12.5-12.7 min. Formation of enzymatically produced non-radioactive N5-2OH-MP (Figure S2 C) was confirmed by HR-MS (ESI-MS) for C₂₀H₄₂B₁₀N₂O₁₀P. Calcd: 609.3580. Found: m/z 609.3612].

S.3. Computational studies

Figure S3: Docked poses of dTMP (A) and N5-2OH-MP (B) in TMPK (PDB ID # 1E2D). In docked poses, carbon atoms are shown in cyan. In co-crystalized dTMP carbon atoms are shown in grey.

Studies were carried out on a Optiplex GX 270 desktop computer/workstation with Windows operating system using PyMoL (DeLano Scientific LLC., San Francisco, CA), Surflex version 2.11 (Biopharmics LLC, San Francisco, CA), and SYBYL-X 1.3 (Tripos International, St. Louis, MO). Human TMPK (PDB ID # 1E2D) complexed with dTMP, adenosine diphosphate (ADP), and Mg^{2+} was used for docking. N5-2OH was constructed as described previously (Tiwari et al. 2009). N5-2OH-MP was prepared by adding a phosphate group to 5'-OH of N5-2OH using Sybyl. N5-2OH-MP was aligned to co-crystalized dTMP prior to docking. The protein structure in mol2 format was prepared with the structure preparation tool of Sybyl. The blocking groups AMI and CXC were added to the N- and C-termini, respectively, for neutralization. Water molecules were removed, hydrogen atoms were added, and side chain amides and side chain bumps were fixed. Both dTMP and ADP were deleted from the crystal structure prior to docking. For docking, the protomol file was generated using the “none” command from the protein mol2 file. Docking was carried out with Surflex using the default method. The root-mean-square deviations (RMSDs) of the docked poses were obtained using the “rms” command. For the calculation of the RMSD of N52OH-MP, only the dThd scaffold was considered using co-crystalized dTMP as a reference molecule.

S.4. Autoradiographic studies

Figure S4. Autoradiogram of a TLC analysis of diphosphate products in TMPK enzyme reactions with dTMP, N5-MP, and N5-2OH-MP.

The assays were performed for 20, 40, and 60 min, as described in *Materials and Methods*. Products of the enzyme reactions were separated by TLC using a running buffer of 0.2 M Na H₂PO₄.

Additional comments: Several sets of experiments were carried out with reaction times ranging from 20 and 60 min. No diphosphate products of N5 and N5-2OH were generated.

Figure S5. Autoradiogram of a TLC analysis of mono- and diphosphate products in the TK1-, UMP-CMPK-, and TMPK enzyme reactions with dThd (A) and AZT (B).

The reaction was initiated by adding either 100 ng of TK1 alone (1, 4); or a mixture of TK1 & UMP-CMPK (2, 5); or a mixture of TK1 & TMPK (3, 6) to the assay followed by incubation at 37 °C for 30 min and subsequent termination by boiling. For the separation of nucleoside mono- and diphosphates in the coupled reactions, chromatography was performed for 8-12 hr using isobutyric acid:NH₄OH:H₂O (66:1:33) (v/v) as the mobile phase. The products were detected by autoradiography as described in *Materials and Methods*.

Additional comments: As a control for the coupled synthesis for each enzyme step, assays were carried out using either TK1 alone or combinations of TK1 with TMPK or UMP-CMPK. An autoradiogram of a TLC analysis of mono and diphosphate products for enzyme reactions with dThd and AZT is shown in Fig. S5. dTMP and AZT-MP are not substrates for UMP-CMPK and only one monophosphate product with TK1 and UMP-CMPK was observed. However, dTMP and AZT-MP are good substrates for TMPK resulting in the formation of dTDP and AZT-DP, respectively, using the TK1/TMPK combination (Fig. S5).

S.5. Figures

Fig. S1




Fig. S2




Fig. S3




Fig. S4





Fig. S5



S.6. List of Abbreviations

AcOH, acetic acid; ACN, acetonitrile; AZT, zidovudine; AZT-MP, AZT monophosphate; AZT-DP, AZT diphosphate; CDCl₃, deuterated chloroform; DCM, dichloromethane; DMF, dimethylformamide; dThd, thymidine; HPLC, high-performance liquid chromatography; HR-ESI, high resolution–electrospray ionization; MeOH, methanol; MeOH-d₄, deuterated methanol; MS, mass spectra; N5, 3-[5-(*o*-carboran-1-yl)pentan-1-yl]thymidine; N5-DP, N5-diphosphate; N5-MP, N5-monophosphate; N5-TP, N5-triphosphate; N5-2OH, 3-[5-{2-(2,3-dihydroxyprop-1-yl)-*o*-carboran-1-yl}pentan-1-yl]thymidine; N5-2OH-MP, N5-2OH monophosphate; TBAF, tetrabutyl ammonium fluoride; TFA, trifluoroacetic acid; THF; tetrahydrofuran; TLC, thin layer chromatography; TK1, thymidine kinase 1; TMPK, thymidine monophosphate kinase; RMSD, root-mean-square deviations; UMP-CMPK, uridine monophosphate-cytidine monophosphate kinase.

S.7. References

- Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S (2004) Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. *Cancer Res* **64**: 6280-6286.
- Davissou VJ, Davis DR, Dixit VM, Poulter CD (1987) Synthesis of nucleotide 5'-diphosphates from 5'-O-tosyl nucleosides. *J Org Chem* **52**: 1794-1801.
- Hasabelnaby S, Goudah A, Agarwal HK, Abd Alla MS, Tjarks W (2012) Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors. *Eur J Med Chem* **55**: 325-334.
- Lunato AJ, Wang J, Woollard JE, Anisuzzaman, AKM, Ji, W, Rong, F-G, Ikeda, S, Soloway, AH, Eriksson, S, Ives, DH et al. (1999) Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. *J Med Chem* **42**: 3378-3389.
- Tiwari T, Mahasenani K, Pavlovicz R, Li C, and Tjarks W. (2009) Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, FlexX, Glide and Surflex. *J Chem Inf Model* **49**: 1581-1589.